CAR T drives acute myeloid leukemia into submission in pre-clinical studies

Investigators have devised a novel method for improving CAR T therapy through a drug combination and cellular engineering that improves the strength and durability of the tumor-killing effect of a CAR T directed against acute myeloid leukemia.